Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/62227
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Effect of maraviroc on HIV disease progression-related biomarkers

AutorRomero-Sánchez, M.; Machmach, K.; González-Serna, Manuel Alejandro; Genebat, Miguel CSIC; Pulido, Ildefonso CSIC ORCID; García-García, María; Álvarez-Ríos, Ana Isabel CSIC ORCID; Ferrando-Martínez, Sara; Ruiz-Mateos, Ezequiel CSIC ORCID; Leal, Manuel CSIC
Fecha de publicación2012
EditorAmerican Society for Microbiology
CitaciónAntimicrobial Agents and Chemotherapy 56(11): 5858-5864 (2012)
ResumenThe potential effect of blocking the CCR5 receptor on HIV disease progression biomarkers is not well understood. We showed that an 8-day maraviroc (MVC) monotherapy clinical test (MCT) can be used in selecting patients to receive MVC-containing combined antiretroviral therapy (cART). Using this MCT model, we assessed the effect of MVC on several HIV disease progression biomarkers during the MCT (MVC-specific effect) and following short-term (12-week) cART. We compared 45 patients on MVC monotherapy with a control group of 25 patients on MVC-sparing cART. We found that MVC did not modify any biomarkers in patients that had no virological response after the MCT. MVC-specific effects in patients with virological responses included increased CD8 + T-cell activation and senescence levels, preservation of an increase in soluble CD14 (sCD14), and a decrease in D dimer levels. After 12 weeks, MVC-containing cART increased CD8 + T-cell counts and preserved CD4 + T-cell senescence levels compared with MVC-sparing cART. Moreover, there was a decrease in sCD14 levels in patients that received MVC-containing cART. In conclusion, effects compatible with CD8 + T-cell redistribution in peripheral blood were observed after MVC therapy. However, MVC was associated with a favorable profile in HIV disease progression biomarkers only in patients with a virological response. These results support a potential clinical benefit of a therapy which includes MVC in HIV-infected patients. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
URIhttp://hdl.handle.net/10261/62227
DOI10.1128/AAC.01406-12
Identificadoresdoi: 10.1128/AAC.01406-12
issn: 0066-4804
Aparece en las colecciones: (IBIS) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

7
checked on 19-mar-2024

SCOPUSTM   
Citations

17
checked on 21-mar-2024

WEB OF SCIENCETM
Citations

17
checked on 23-feb-2024

Page view(s)

326
checked on 29-mar-2024

Download(s)

108
checked on 29-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.